Literature DB >> 24684226

Risk adapted therapy for multiple myeloma: back to basics.

Shaji K Kumar1, Morie A Gertz.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24684226     DOI： 10.3109/10428194.2014.905775

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  6 in total

1.  Establishment of a human multiple myeloma xenograft model in the chicken to study tumor growth, invasion and angiogenesis.

Authors:  Agnieszka Martowicz; Johann Kern; Eberhard Gunsilius; Gerold Untergasser
Journal:  J Vis Exp       Date:  2015-05-01       Impact factor: 1.355

2.  Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.

Authors:  Tan-Huy Chu; Manh-Cuong Vo; Hye-Seong Park; Thangaraj Jaya Lakshmi; Sung-Hoon Jung; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Cancer Immunol Immunother       Date:  2020-07-04       Impact factor: 6.968

Review 3.  Risk factors in multiple myeloma: is it time for a revision?

Authors:  Jill Corre; Nikhil C Munshi; Hervé Avet-Loiseau
Journal:  Blood       Date:  2021-01-07       Impact factor: 25.476

4.  Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.

Authors:  Manh-Cuong Vo; Seoyun Yang; Sung-Hoon Jung; Tan-Huy Chu; Hyun-Ju Lee; Thangaraj Jaya Lakshmi; Hye-Seong Park; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Front Immunol       Date:  2018-08-03       Impact factor: 7.561

5.  Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells.

Authors:  Manh-Cuong Vo; Thanh-Nhan Nguyen-Pham; Hyun-Ju Lee; Sung-Hoon Jung; Nu-Ri Choi; My-Dung Hoang; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Oncotarget       Date:  2017-07-11

6.  Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma.

Authors:  Manh-Cuong Vo; Sung-Hoon Jung; Tan-Huy Chu; Hyun-Ju Lee; Thangaraj Jaya Lakshmi; Hye-Seong Park; Hyeoung-Joon Kim; Joon Haeng Rhee; Je-Jung Lee
Journal:  Front Immunol       Date:  2018-06-18       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.